Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) has received an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $28.25.
A number of brokerages recently weighed in on BMEA. Citigroup lowered their target price on shares of Biomea Fusion from $90.00 to $45.00 and set a “buy” rating on the stock in a research note on Friday, June 7th. Oppenheimer lowered their target price on shares of Biomea Fusion from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Thursday, May 30th. Scotiabank lowered their target price on shares of Biomea Fusion from $41.00 to $21.00 and set a “sector outperform” rating on the stock in a research note on Friday, June 7th. Piper Sandler lowered their target price on shares of Biomea Fusion from $45.00 to $10.00 and set an “overweight” rating on the stock in a research note on Friday, June 7th. Finally, JPMorgan Chase & Co. raised their target price on shares of Biomea Fusion from $14.00 to $15.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd.
Get Our Latest Analysis on BMEA
Institutional Inflows and Outflows
Biomea Fusion Trading Up 0.7 %
Shares of Biomea Fusion stock opened at $5.87 on Wednesday. Biomea Fusion has a 12-month low of $3.61 and a 12-month high of $22.74. The company has a market cap of $211.00 million, a price-to-earnings ratio of -1.64 and a beta of -0.52. The company’s 50-day moving average price is $5.26 and its 200-day moving average price is $10.74.
Biomea Fusion (NASDAQ:BMEA – Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported ($1.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.03). On average, sell-side analysts predict that Biomea Fusion will post -4.09 earnings per share for the current year.
About Biomea Fusion
Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
See Also
- Five stocks we like better than Biomea Fusion
- Find and Profitably Trade Stocks at 52-Week Lows
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Basic Materials Stocks Investing
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.